Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
Clinical Trial 20040
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT03712605
Phase: Phase III
Prinicipal Investigator: Andrew Brohl
Study Title
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Summary
Objective
To compare Overall Survival (OS) and Recurrence Free Survival (RFS) as co-primary endpoints across the two arms. To evaluate adverse events. To evaluate Distant Metastasis Free Survival (DMFS). To evaluate the impact of radiation on clinical outcomes (OS, RFS, DMFS).
Therapies
Medications
Pembrolizumab (Keytruda)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.